Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy

• Published in: The American heart journal Vol. 156; no. 1; pp. 85 - 91
• Main Authors: Roldán, Vanessa, MD, PhD, Marín, Francisco, MD, PhD, Gimeno, Juan R., MD, PhD, Ruiz-Espejo, Francisco, MD, González, Josefa, MD, Feliu, Eloisa, MD, PhD, García-Honrubia, Antonio, MD, Saura, Daniel, MD, de la Morena, Gonzalo, MD, Valdés, Mariano, PhD, Vicente, Vicente, PhD
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01-07-2008; Elsevier; Elsevier Limited
• Subjects: Adult; Biological and medical sciences; Biomarkers - blood; Cardiac arrhythmia; Cardiology. Vascular system; Cardiomyopathy; Cardiomyopathy, Hypertrophic - blood; Cardiomyopathy, Hypertrophic - diagnosis; Cardiomyopathy, Hypertrophic - mortality; Cardiovascular; Case-Control Studies; Cohort Studies; Collagen; Enzyme-Linked Immunosorbent Assay; Female; Fitness equipment; Gadolinium DTPA; Heart; Heart attacks; Heart failure; Hospitals; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 1 - blood; Matrix Metalloproteinase 2 - blood; Matrix Metalloproteinase 9 - blood; Matrix Metalloproteinases - blood; Medical sciences; Middle Aged; Multivariate analysis; Myocarditis. Cardiomyopathies; Probability; Prognosis; Reference Values; Risk factors; Sensitivity and Specificity; Severity of Illness Index; Software; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1 - blood; Ventricular Remodeling - physiology; Vascular remodeling; Peptidases; Tissue; Enzyme; Heart disease; Hypertrophic cardiomyopathy; Hydrolases; Metalloendopeptidases; Cardiovascular disease; Circulatory system; Cardiology; Myocardial disease
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1016/j.ahj.2008.01.035

Background Hypertrophic cardiomyopathy (HCM) is defined by the presence of unexplained left ventricular hypertrophy, myocyte disarray, and interstitial fibrosis. An increase in extracellular matrix produces interstitial fibrosis, by raised amounts of collagen type I/III. Regions of myocardial late gadolinium enhancement by cardiac magnetic resonance (CMR) represented increased myocardial collagen. Regarding the role of matrix metalloproteinases (MMPs) in myocardial remodeling and subsequent fibrosis, the aim of our study was to explore the relation between MMP system and myocardial late gadolinium enhancement by CMR (as expression of image-documented fibrosis) and N-terminal pro-brain natriuretic peptide (NT-proBNP) (as a marker of cardiac overload) in HCM. Methods We included 67 HCM patients (44 men aged 49 ± 14 years) and were compared to 58 controls with similar age and sex. Risk factors for sudden death were recorded. A blinded CMR was performed with gadolinium. Matrix metalloproteinase 1, MMP-2, and MMP-9 plasma levels were assayed by enzyme-linked immunosorbent assay. Serum samples were used for measurement of NT-proBNP. Results In patients, >50% of MMP-1 values were below the lowest limit of detection of the technique. Raised levels of MMP-2, MMP-9, and NT-proBNP were observed in HCM patients (all P < .01). Matrix metalloproteinase 2 was associated with dyspnea ( P = .049) and correlated with MMP-9 ( r = 0.28, P = .025) and NT-proBNP ( r = 0.39, P = .001). Matrix metalloproteinase 9 was associated with the presence of gadolinium enhancement in CMR ( P = .001) and correlated with NT-proBNP ( r = 0.52, P < .001). NT-proBNP was also associated with gadolinium enhancement ( P = .006). Both MMP-2 and MMP-9 correlated negatively with exercise capacity (metabolic equivalent units), ( r = −0.36 and r = −0.42 respectively, both P < .01). On multivariate analysis (adjusted by sudden death risk factors and echocardiographic markers), only MMP-9 was associated with fibrosis ( P = .011). Conclusions Matrix metalloproteinase 9 is independently associated with gadolinium enhancement on CMR in patients with hypertrophic cardiomyopathy, suggesting that the MMP system has an important role in cardiac remodeling and fibrosis in this condition.